Quarterly report [Sections 13 or 15(d)]

SEGMENTS

v3.26.1
SEGMENTS
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SEGMENTS

11. SEGMENTS

 

The Company operates and manages its business as a single reporting segment. The business provides esoteric molecular diagnostic testing, and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer from clinical features. We develop and commercialize genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. The Company’s chief operating decision maker (“CODM”) is the chief executive officer.

 

The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net income that is also reported on the consolidated statements of operations. The monitoring of budgeted versus actual results is used in assessing performance of the segment and in establishing resource allocation across the organization.

 

The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. All the Company’s long-lived assets are located in the United States. The accounting policies of the segment are the same as those described in Note 1, Nature of Business and Significant Accounting Policies included in our Annual Report on Form 10-K.

 

 

The following table presents reportable segment profit and loss, including significant expense categories, attributable to the Company’s reportable segment for the periods presented:

 

         
    For The Three Months Ended  
    March 31,  
    2026     2025  
             
Revenue, net:   $ 9,032     $ 11,515  
Less:                
Cost of revenue:                
Fixed     1,697       1,690  
Variable     1,431       2,455  
Operating and other expenses:                
Sales and marketing     2,177       2,814  
Research and development     153       177  
General and administrative     2,451       2,550  
Other (income) expense, net     (10 )     57  
Provision for income taxes     302       18  
Segment net income     831       1,754  
Reconciliation of profit or loss:                
Loss on discontinued operations     (110 )     (107 )
Consolidated net income   $ 721     $ 1,647  

 

Adjusted EBITDA, a non-GAAP financial measure, is a metric used by the CODM to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock-based compensation, non-recurring legal expenses, severance expense, interest and taxes, and other non-cash expenses including change in fair value of notes payable. The legal expenses included are related to NASDAQ uplist costs, special proxy and charter work, and an employment dispute. The table below includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

 

Reconciliation of Adjusted EBITDA (Unaudited)

($ in thousands)

 

         
    Three Months Ended  
    March 31,  
    2026     2025  
Income from continuing operations (GAAP Basis)   $ 831     $ 1,754  
Depreciation and amortization     118       95  
Stock-based compensation     4       15  
Severance expense     -       168  
Taxes expense     302       18  
Non-recurring legal expenses     315       -  
Note payable interest     -       78  
Interest income     (10 )     (7 )
Change in fair value of note payable     -       (25 )
Adjusted EBITDA   $ 1,560     $ 2,096